About us
Our name, Enara Bio®, is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.
We are the leaders in discovering and validating Dark Antigens®, a rich source of novel cancer targets derived from areas of the genome previously considered to be ‘dark’ or non-coding. Through our proprietary EnTiCE® platform, we are developing first-in-class bispecific T-cell engagers against novel targets to improve treatment outcomes for broad populations of cancer patients.
Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.
Leadership Team
President and CEO
CBO and CFO
CMO
CSO
Board of Directors
Scientific Advisors & Founders
-
George Kassiotis, PhD
Co-founder of Enara Bio
Francis Crick Institute -
Mike Quigley, PhD
Sanofi CSO and Global Head of Research
Ex-Gilead and BMS R&D -
Drew Pardoll, MD PhD
Co-founder of Enara Bio
Johns Hopkins School of Medicine - Eliezer Van Allen, MD PhD Dana-Farber Cancer Institute / Harvard
-
Houman Ashrafian
Co-founder of Enara Bio
Sanofi EVP, Head of R&D -
Katherine Chiappinelli, PhD
Associate Professor
George Washington University Cancer Center
